<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53827">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02140931</url>
  </required_header>
  <id_info>
    <org_study_id>HS 12-01</org_study_id>
    <nct_id>NCT02140931</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia</brief_title>
  <official_title>A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemostemix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemostemix</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind placebo controlled study to determine the safety and efficacy of
      Angiogenic Cell Precursors (ACPs) in relieving symptoms of Critical Limb Ischemia in
      patients treated with standard of care and with no surgical revascularization option. It is
      assumed that the ACP-treated group will have a lower amputation and death rate as compared
      to the placebo group. Other hemodynamic, imaging and clinical parameters will also be
      compared between the two groups. Quality of life assessments will also be performed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to major amputation / mortality</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the level of pain in the treated ischemic leg</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the quantity of analgesic drugs used by the patient</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ABI (Ankle Brachial Index)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline  in TBI (Toe Brachial Index)</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ulcer size</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospitalization time of ACP-treated patients compared to controls</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety of intramuscular injection of ACPs</measure>
    <time_frame>26 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Vital signs
Physical examination
Clinical laboratory values
Electrocardiograms
Adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Angiogenic Cell Precursors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cell culture medium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intra-muscular injections of cell culture medium in the ischemic leg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Angiogenic Cell Precursors</intervention_name>
    <arm_group_label>Angiogenic Cell Precursors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is diagnosed with critical limb ischemia

          -  Patient has hemodynamic indicators of severe peripheral arterial disease

          -  Patient is not a candidate for revascularization treatment options for peripheral
             arterial disease

          -  Patient is on standard of care medical therapy for peripheral arterial disease

          -  Male or female age 18 and above

          -  Non-pregnant, non-lactating female

          -  Patient is able to understand and provide a signed informed consent form

        Exclusion Criteria:

          -  Patient having an uncorrected Aorto-Iliac occlusive disease down to the origin of the
             Profunda-Femoris artery

          -  Patient who in the opinion of the investigator would require a major amputation
             within approximately 4 weeks after administration of study treatment.

          -  Critical Limb Ischemia presenting as severe large ischemic ulcers or dry gangrene
             proximal to the MTP (Metatarsophalangeal) joints heads or lower extremity wet
             gangrene

          -  Lower extremity non-treated active infection

          -  Hypercoagulable state

          -  Patient received blood transfusions during the previous 4 weeks

          -  Patient's condition precludes 2 consecutive attempts of ACPs manufacturing

          -  Patient unable to communicate

          -  Major non-vascular operation during the preceding 3 months

          -  Myocardial infarction or uncontrolled myocardial ischemia or persistent severe heart
             failure during the preceding 3 months

          -  Severe aortic stenosis

          -  Severe renal failure

          -  Severe hepatic failure

          -  Anemia

          -  Major stroke within the preceding 3 months.

          -  Diagnosis of malignancy within the preceding 3 years

          -  Concurrent chronic or acute infectious disease and uncontrolled infectious symptoms

          -  Severe concurrent disease

          -  Bleeding diathesis.

          -  Participation at the same time in another stem cell study

          -  Chronic immunomodulating or cytotoxic drug treatment

          -  Fever for 2 days prior to the time the patient is about to receive the study
             treatment

          -  Life expectancy of less than 6 months

          -  Patient unlikely to be available for follow-up

          -  No acute worsening of CLI (Critical Limb Ischemia)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas F. Lindsay, MDCM Msc BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Al-Omran, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>York N. Hsiang, MB ChB MHSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vancouver General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eli Braude, MD</last_name>
    <phone>+972.54.9020120</phone>
    <email>ebraude@hemostemix.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentin Fulga, MD</last_name>
    <phone>1.416.720.0573</phone>
    <email>valentin@hemostemix.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1K3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>York N. Hsiang, MB ChB MHSc</last_name>
      <phone>604.876.5882</phone>
      <email>york.hsiang@vch.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas F. Lindsy, MDCM Msc BSc</last_name>
      <phone>416.340.4800</phone>
      <phone_ext>4620</phone_ext>
      <email>thomas.lindsay@uhn.on.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohammed Al-Omran, MD MSc</last_name>
      <phone>416-864-6047</phone>
      <email>alomranm@smh.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.hemostemix.com/</url>
    <description>Hemostemix web site</description>
  </link>
  <reference>
    <citation>Szabó GV, Kövesd Z, Cserepes J, Daróczy J, Belkin M, Acsády G. Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-results of the short- and long-term follow-up. Cytotherapy. 2013 Oct;15(10):1245-52. doi: 10.1016/j.jcyt.2013.05.017.</citation>
    <PMID>23993298</PMID>
  </reference>
  <reference>
    <citation>Porat Y, Porozov S, Belkin D, Shimoni D, Fisher Y, Belleli A, Czeiger D, Silverman WF, Belkin M, Battler A, Fulga V, Savion N. Isolation of an adult blood-derived progenitor cell population capable of differentiation into angiogenic, myocardial and neural lineages. Br J Haematol. 2006 Dec;135(5):703-14.</citation>
    <PMID>17052254</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>May 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>Autologous</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
